TRANSFER OF GRANT - REGULATION OF LIMDAZOLINE SITES
授权转让 - 利咪唑啉场所的监管
基本信息
- 批准号:3388702
- 负责人:
- 金额:$ 7.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1993
- 资助国家:美国
- 起止时间:1993-09-01 至 1995-06-30
- 项目状态:已结题
- 来源:
- 关键词:G protein alkylating agents antidepressants clinical depression clone cells clonidine fluorescence polarization genetic manipulation hormone regulation /control mechanism human tissue hypothalamus imidazole megakaryocytes menstrual cycle molecular cloning neoplastic cell nucleic acid sequence platelets polymerase chain reaction radiotracer receptor binding receptor expression tissue /cell culture
项目摘要
During his FIRST award, Dr. Piletz (the P.I.) and colleagues obtained
evidence that non-adrenergic, imidazoline-selective receptors may be linked
to depression. They found that unipolar depressed patients displayed a
significant elevation (p=.002) in the binding density (Bmax) of p-125 IC)
to an imidazoline-selective site on platelets, compared to healthy controls
or patients with generalized anxiety disorder. The site on platelet plasma
membranes was nearly identical to the Imidazoline-1 Receptor (I1R) in brain
stem based on its affinity for a variety of compounds. Platelet p125 IC
binding declined in patients following antidepressant drug treatment.
Additionally, the binding of an analogue, p-NH4-3H-clonidine, was
significantly elevated in the late luteal phase of women with dysphoric
premenstrual changes (PMS), but not in women with normal menstrual cycles.
In this application Dr. Piletz teams up with the discoverer of the I1R (Dr.
Ernsberger) to investigate the molecular basis of regulation of I1 binding
sites. A human megakaryocytic tumor cell line (MEG-01) will be used as a
model of platelet receptors. This unique cell line was shown by Dr. Piletz
to possess I1 sites, and can actually produce platelet-like particles in
culture. Drawing on Dr. Piletz's postdoctoral experience with cDNA, and on
a team of colleagues who have cloned similar receptors, this application
proposes to clone the I1 receptor cDNA in MEG-01 cells. These studies will
answer fundamental questions about the platelet I1 site, its regulation in
health and disease and its possible utility as a marker in depressive
illness and PMS.
在他的第一个奖项,皮莱茨博士(私家侦探)和他的同事获得
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN E PILETZ其他文献
JOHN E PILETZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN E PILETZ', 18)}}的其他基金
AGMATINASE INHIBITORS FOR HYPOXIC-ISCHEMIC NEW BORN BRAIN DAMAGE
胍丁胺酶抑制剂治疗新生儿缺氧缺血性脑损伤
- 批准号:
7076306 - 财政年份:2006
- 资助金额:
$ 7.57万 - 项目类别:
AGMATINASE INHIBITORS FOR HYPOXIC-ISCHEMIC NEW BORN BRAIN DAMAGE
胍丁胺酶抑制剂治疗新生儿缺氧缺血性脑损伤
- 批准号:
7285421 - 财政年份:2006
- 资助金额:
$ 7.57万 - 项目类别:
AGMATINASE INHIBITORS FOR HYPOXIC-ISCHEMIC NEW BORN BRAIN DAMAGE
胍丁胺酶抑制剂治疗新生儿缺氧缺血性脑损伤
- 批准号:
7273890 - 财政年份:2006
- 资助金额:
$ 7.57万 - 项目类别:
IMIDAZOLINE RECEPTORS IN DEPRESSION--BASIC STUDIES
抑郁症中的咪唑啉受体——基础研究
- 批准号:
2890501 - 财政年份:1993
- 资助金额:
$ 7.57万 - 项目类别:
IMIDAZOLINE RECEPTORS IN DEPRESSION--BASIC STUDIES
抑郁症中的咪唑啉受体——基础研究
- 批准号:
2631091 - 财政年份:1993
- 资助金额:
$ 7.57万 - 项目类别:
IMIDAZOLINE RECEPTORS IN DEPRESSION--BASIC STUDIES
抑郁症中的咪唑啉受体——基础研究
- 批准号:
6392016 - 财政年份:1993
- 资助金额:
$ 7.57万 - 项目类别:
IMIDAZOLINE RECEPTORS IN DEPRESSION--BASIC STUDIES
抑郁症中的咪唑啉受体——基础研究
- 批准号:
6186566 - 财政年份:1993
- 资助金额:
$ 7.57万 - 项目类别:
REGULATION OF IMIDAZOLINE BINDING SITES IN DEPRESSION
抑郁状态下咪唑啉结合位点的调节
- 批准号:
3388701 - 财政年份:1992
- 资助金额:
$ 7.57万 - 项目类别:
相似海外基金
Differential resistance mechanisms to monofunctional vs bifunctional alkylating agents in glioma
神经胶质瘤对单功能烷化剂与双功能烷化剂的不同耐药机制
- 批准号:
10374792 - 财政年份:2021
- 资助金额:
$ 7.57万 - 项目类别:
Elucidation and prevention of the mechanism of hepatic sinusoidal obstruction syndrome (SOS) induced by DNA alkylating agents
DNA烷化剂诱发肝窦阻塞综合征(SOS)机制的阐明和预防
- 批准号:
21K15255 - 财政年份:2021
- 资助金额:
$ 7.57万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Differential resistance mechanisms to monofunctional vs bifunctional alkylating agents in glioma
神经胶质瘤对单功能烷化剂与双功能烷化剂的不同耐药机制
- 批准号:
10570900 - 财政年份:2021
- 资助金额:
$ 7.57万 - 项目类别:
Development of individualized therapy by elucidation of molecular mechanisms for hypermutation phenotype induced by treatment with alkylating agents in glioma
通过阐明神经胶质瘤中烷化剂治疗诱导的超突变表型的分子机制来开发个体化治疗
- 批准号:
18K09004 - 财政年份:2018
- 资助金额:
$ 7.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Reversing intrinsic cancer cell resistance to alkylating agents by histone deacetylase inhibition
通过组蛋白脱乙酰酶抑制逆转癌细胞对烷化剂的内在耐药性
- 批准号:
214657440 - 财政年份:2012
- 资助金额:
$ 7.57万 - 项目类别:
Research Grants
Rerouting alkylating agents to the mitochondria for cancer therapy
将烷化剂重新路由至线粒体用于癌症治疗
- 批准号:
247842 - 财政年份:2011
- 资助金额:
$ 7.57万 - 项目类别:
Studentship Programs
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
- 批准号:
8105413 - 财政年份:2010
- 资助金额:
$ 7.57万 - 项目类别:
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
- 批准号:
8271313 - 财政年份:2010
- 资助金额:
$ 7.57万 - 项目类别:
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
- 批准号:
8730259 - 财政年份:2010
- 资助金额:
$ 7.57万 - 项目类别:
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
- 批准号:
8676463 - 财政年份:2010
- 资助金额:
$ 7.57万 - 项目类别: